Display options
Cite
Reyburn R, Tuivaga EJ, Ratu FT, et al. The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji. Lancet Reg Health West Pac. 2022;20:100352doi: 10.1016/j.lanwpc.2021.100352.
Reyburn, R., Tuivaga, E. J., Ratu, F. T., Dunne, E. M., Nand, D., Kado, J., Jenkins, K., Tikoduadua, L., Jenney, A., Howden, B. P., Ballard, S. A., Fox, K., Devi, R., Satzke, C., Rafai, E., Kama, M., Flasche, S., Mulholland, E. K., & Russell, F. M. (2022). The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji. The Lancet regional health. Western Pacific, 20100352. https://doi.org/10.1016/j.lanwpc.2021.100352
Reyburn, R, et al. "The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji." The Lancet regional health. Western Pacific vol. 20 (2022): 100352. doi: https://doi.org/10.1016/j.lanwpc.2021.100352
Reyburn R, Tuivaga EJ, Ratu FT, Dunne EM, Nand D, Kado J, Jenkins K, Tikoduadua L, Jenney A, Howden BP, Ballard SA, Fox K, Devi R, Satzke C, Rafai E, Kama M, Flasche S, Mulholland EK, Russell FM. The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji. Lancet Reg Health West Pac. 2022 Jan 05;20:100352. doi: 10.1016/j.lanwpc.2021.100352. eCollection 2022 Mar. PMID: 35028629; PMCID: PMC8741523.
Copy Download .nbib Format: NLM
Share it on

Lancet Reg Health West Pac. 2022 Jan 05;20:100352. doi: 10.1016/j.lanwpc.2021.100352. eCollection 2022 Mar.

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji.

The Lancet regional health. Western Pacific

R Reyburn, E J Tuivaga, F T Ratu, E M Dunne, D Nand, J Kado, K Jenkins, L Tikoduadua, A Jenney, B P Howden, S A Ballard, K Fox, R Devi, C Satzke, E Rafai, M Kama, S Flasche, E K Mulholland, F M Russell

Affiliations

  1. Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  2. The Ministry of Health and Medical Services, Suva, Fiji.
  3. Fiji National University, Suva, Fiji.
  4. Australia's support to the Fiji health sector, Suva, Fiji.
  5. Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia.
  6. Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne, Australia.
  7. WHO Regional Reference Laboratory for Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) for Western Pacific Region, Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne, Australia.
  8. Regional Office for the Western Pacific, World Health Organization, Manila, Philippines.
  9. Centers for Disease Control and Prevention, Atlanta, GA, USA.
  10. Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
  11. Centre for Mathematical Modelling for Infectious diseases, London School of Hygiene and Tropical Medicine, London, UK.
  12. Centre for International Child Health, Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.

PMID: 35028629 PMCID: PMC8741523 DOI: 10.1016/j.lanwpc.2021.100352

Abstract

BACKGROUND: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction.

METHODS: Laboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data.

FINDINGS: There were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively.

INTERPRETATIONS: Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data.

FUNDING: This study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government.

© 2021 The Authors.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationshipsthat could have appeared to influence the work reported in this paper.

Publication Types